A randomized pilot clinical trial of pravastatin versus placebo in pregnant patients at high risk of preeclampsia.

ABSTRACT:

Background

Preeclampsia remains a major cause of maternal and neonatal morbidity and mortality. Biologic plausibility, compelling preliminary data, and a pilot clinical trial support the safety and utility of pravastatin for the prevention of preeclampsia.

Objective

We previously reported the results of a phase I clinical trial using a low dose (10 mg) of pravastatin in high-risk pregnant women. Here, we report a follow-up, randomized trial of 20 mg pravastatin versus placebo among pregnant women with previous preeclampsia who required delivery before 34+6 weeks' gestation with the objective of evaluating the safety and pharmacokinetic parameters of pravastatin.

Study design

This was a pilot, multicenter, blinded, placebo-controlled, randomized trial of women with sin

SUBMITTER: Costantine MM 

PROVIDER: S-EPMC8611118 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature